JPRN-jRCT2080223797已完成3 期
An open-label extension study of phase 3 clinical trial of duloxetine in children and adolescents with depressive disorder
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 9age old 至 <= 17age old（—）
- 性别
- All
入选标准
- •Consecutive Participants:
- •Patients who have completed the 7-week treatment in the preceding study (A phase 3 clinical trial of duloxetine in children and adolescents with depressive disorder)
- •New Participants:
- •Patients who diagnosed with major depressive disorder or persistent depressive disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and completely meet the criteria of major depressive episode. And et al.
排除标准
- •Patients who have allergies to two or more medicines or have a history of severe allergic reactions with medicines. And et al.
研究者
相似试验
未知
3 期
An open label extension study of phase 3 clinical trial of duloxetine in patients with chronic low back paiJPRN-jRCT2080222263SHIONOGI & CO., LTD.
未知
3 期
An open label extension study of phase 3 clinical trial of duloxetine in patients with osteoarthritisosteoarthritisJPRN-jRCT2080222774Shionogi & Co., Ltd.
未知
3 期
An Open Label Extension Study of Phase III Clinical Trial of Duloxetine in Patients With FibromyalgiaFibromyalgiaJPRN-jRCT2080221803SHIONOGI & CO., LTD.
已完成
3 期
A Phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in Study M16-046Eczema1000381610014982Atopic DermatitisNL-OMON55265AbbVie Deutschland GmbH & Co. KG15
进行中（未招募）
1 期
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the M16-046 study. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completedModerate to severe Atopic DermatitisMedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858EUCTR2019-001227-12-IEAbbVie Deutschland GmbH & Co. KG485